AI assistant
AGENUS INC — Director's Dealing 2017
Dec 14, 2017
34023_dirs_2017-12-14_bf844e62-fb5a-4bee-9be8-86cb77f7536d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AGENUS INC (AGEN)
CIK: 0001098972
Period of Report: 2017-10-09
Reporting Person: ARMEN GARO H (CEO and Chairman of the Board)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-09 | Common Stock | A | 71966 | $3.59 | Acquired | 1362407 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 304046 | Indirect |
Footnotes
F1: Represents settlement of restricted shares awarded on July 1, 2015.
F2: Dr. Armen is trustee and has investment authority for the Garo Armen 2017 2 year AG GRAT holding 300,000 shares of Agenus Inc. common stock. Dr. Armen disclaims beneficial ownership therein. Dr. Armen is Chairman of the Board of Mangers and a member of Antigenics Holdings LLC ("Holdings") which as of the date of this report owns 4,046 shares of Agenus Inc. common stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Holdings and disclaims beneficial ownership to the extent of his pecuniary interest therein.